6-K - Nasus Pharma Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Nasus Pharma announced positive Phase 2 topline results for NS002 intranasal epinephrine, demonstrating statistically significant improvements in early absorption versus EpiPen, with a pivotal study planned for Q4 2026. The company reported 2025 annual results including $4.3 million cash and $5.9 million net loss, with cash runway to Q2 2027 following $15 million private placement.

Key Takeaways

1NS002 Phase 2 results: statistically significant improvements in time to T100 and early therapeutic levels vs EpiPen

2NS002 pivotal study initiation: Q4 2026, readout Q1 2027

3NS003 and NS004 first-in-human studies: H2 2026

4Cash, cash equivalents, marketable securities: $4.3 million as of Dec 31, 2025 (vs $0.3 million Dec 31, 2024)

5Net loss: $5.9 million for year ended Dec 31, 2025 (vs $1.5 million 2024)

6$15 million private placement closed Feb 2026, funding to Q2 2027

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Results of Operations

Year ended December 31, 2025

Metric	Value	Prior Period
Research and Development Expenses	$2.40	$0.30
General and Administrative Expenses	$2.70	$0.70
Net Loss	$5.90	$1.50

Exhibits (2)

6-K

99.1

EX-99.1